Motilal Oswal has issued a Neutral rating on Alkem Lab with a target price of Rs 5525 in its research report dated February 14, 2026. According to the broker's analysis, the company is advancing its MedTech strategy through a significant acquisition that aligns with its broader diversification efforts.
Alkem Lab is acquiring up to a 55% stake in Occlutech for approximately EUR 99 million (around INR 10.6 billion). As reported by Motilal Oswal, Occlutech is a leading structural heart and closure device company with over 10 product lines, presence in more than 70 countries, and manufacturing in Germany and Turkey. The company has sold over 200,000 devices and ranks as the third-largest player in the global occluder segment. Occlutech develops, manufactures, and commercializes medical devices for congenital heart disease, stroke prevention and heart failure.
Occlutech has demonstrated strong growth with approximately 17% revenue CAGR over CY22-24, generating EUR 43 million in CY24 and an estimated EUR 49 million in CY25. According to Motilal Oswal's analysis, the company's CY25 revenue, EBITDA, and loss stand at approximately EUR 49 million, EUR 2 million, and EUR 6.8 million respectively. The company currently operates with single-digit margins of around 5% and is targeting expansion to 23-24% margins over the next 3-4 years.
Motilal Oswal has reduced earnings estimates by 4%/5% for FY27/FY28 due to increased raw material prices from the implementation of MIP by the government of India and ongoing weakness in certain therapies in the DF segment. The broker values Alkem Lab at 28x 12-month forward earnings to arrive at the target price of Rs 5525. Despite these challenges, the acquisition supports the company's diversification into the MedTech and CDMO space alongside its domestic formulations segment.
The acquisition aligns with Alkem Lab's broader MedTech focus on musculoskeletal and cardiovascular segments within a large global opportunity of USD 680 billion MedTech and USD 87 billion Cardiovascular markets. As reported by Motilal Oswal, the company has already established a base in orthopedics through a hybrid entry model and the Bombay Ortho acquisition. The transaction supports Alkem Lab's diversification into the MedTech and CDMO space alongside its domestic formulations segment.
Motilal Oswal expects 10.5%/12% CAGR in revenue/EBITDA over FY26-28 for Alkem Lab. According to the broker's analysis, earnings are expected to remain stable over FY26-28 due to a step-up in tax rate. The valuation adequately factors in the upside potential, leading to the Neutral rating recommendation on the stock despite the revised outlook reflecting current market challenges.
